Severe, persistent pain in the upper abdomen — often boring through to the back — with nausea and vomiting that will not stop. That is the pancreatitis pattern.
Stop and seek medical assessment. Persistent vomiting also dehydrates and strains the kidneys — sip fluids.
Unrelenting abdominal pain, repeated vomiting, or signs of dehydration → urgent care or ER. And tell any anaesthetist before surgery: these drugs slow stomach emptying and raise the risk of aspiration under anaesthesia.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
Built on an oxyntomodulin scaffold — a naturally occurring gut peptide that is itself a dual glucagon/GLP-1 agonist — rather than engineered from GLP-1 outward. The glucagon arm drives energy expenditure and hepatic fat mobilisation; the GLP-1 arm supplies appetite suppression and offsets glucagon's hyperglycaemic tendency.
Substantial Chinese phase 3 programme. The GLORY-2 study reported up to 20.1% weight reduction at the 9 mg dose, meeting primary and all key secondary endpoints. Evidence quality here is real and modern — the limitation is that it has been generated predominantly in Chinese populations and has not been reviewed by FDA.
Approved in China by the NMPA — for chronic weight management (June 2025) and for glycaemic control in type 2 diabetes (September 2025). It is the world's first dual GCG/GLP-1 agonist to reach approval anywhere. Not FDA-approved and not lawfully marketed in the US.
Trial safety data exist. Gastrointestinal effects and heart-rate increase, consistent with the class. Approval outside the US does not mean FDA has reviewed the dossier.
Approved in China; the GLORY phase 3 programme used up to 9 mg once weekly SC. Not reviewed by the FDA.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.